Public Health Emergency - Leading a Nation Prepared
The SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the Atellica® IM system. Siemens has over 2,000 fully automated immunoassay analyzers in hospitals and mid- to high-volume reference laboratories across all 50 states. The analyzers include the Atellica® IM which can run up to 440 tests/hour ith result in 10 minutes and the ADVIA Centaur® XP & XPT analyzers, which can test up to 240 samples/hour with result in 18 minutes.
On July 31, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Siemens Healthineers’ Atellica ® IM SARS-CoV-2 Total (COV2T) assay to be used to identify individuals with an adaptive immune response to SARS-CoV-2, indicating prior or recent infection.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages